RJA
VBIV

Raymond James & Associates’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Raymond James & Associates’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,313
Closed -$13K – 4241
2021
Q1 		$13K Sell
1,313
-960
-42% -$97.3K ﹤0.01% 3947
2020
Q4 		$31K Sell
2,273
-1,067
-32% -$91K ﹤0.01% 3661
2020
Q3 		$48K Buy
3,340
+2,073
+164% +$242K ﹤0.01% 3451
2020
Q2 		$44K Buy
+1,267
New +$69.8K ﹤0.01% 3388

Other funds holding VBIV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James & Associates's VBIV Position: Q2 2023 in Review

Raymond James & Associates sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2023, closing a stake of 6,127 shares — an estimated $55.7K sold.

Raymond James & Associates first reported a position in VBIV in Q4 2019 and held it in 14 quarters. The position peaked at $2.7M in Q2 2021. 46 funds tracked by Wall St. Rank hold VBIV as of Q2 2023.

  • Raymond James & Associates reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2023 after selling out during the quarter.
  • Raymond James & Associates sold 6,127 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2023, an estimated $55.7K.
  • Raymond James & Associates first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2019 and held it in 14 quarters.
  • Raymond James & Associates's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $2.7M in Q2 2021.
  • 46 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2023.

Based on Raymond James & Associates's 13F filing for Q2 2023, filed 25 Jul 2023.